Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study
Background: COVID-19 may be more frequent and more severe in cancer patients than in other individuals. Our aims were to assess the rate of COVID-19 in hospitalized cancer patients, to describe their demographic characteristics, clinical features and care trajectories, and to assess the mortality ra...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/19/4749 |
| _version_ | 1797516738428928000 |
|---|---|
| author | Marc-Antoine Benderra Ainhoa Aparicio Judith Leblanc Demian Wassermann Emmanuelle Kempf Gilles Galula Mélodie Bernaux Anthony Canellas Thomas Moreau Ali Bellamine Jean-Philippe Spano Christel Daniel Julien Champ Florence Canouï-Poitrine Joseph Gligorov on Behalf of the AP-HP/Universities/INSERM COVID-19 Research Collaboration Cancer AP-HP Group COVID-19 Task Force AP-HP Covid CDW Initiative (ACCI) |
| author_facet | Marc-Antoine Benderra Ainhoa Aparicio Judith Leblanc Demian Wassermann Emmanuelle Kempf Gilles Galula Mélodie Bernaux Anthony Canellas Thomas Moreau Ali Bellamine Jean-Philippe Spano Christel Daniel Julien Champ Florence Canouï-Poitrine Joseph Gligorov on Behalf of the AP-HP/Universities/INSERM COVID-19 Research Collaboration Cancer AP-HP Group COVID-19 Task Force AP-HP Covid CDW Initiative (ACCI) |
| author_sort | Marc-Antoine Benderra |
| collection | DOAJ |
| description | Background: COVID-19 may be more frequent and more severe in cancer patients than in other individuals. Our aims were to assess the rate of COVID-19 in hospitalized cancer patients, to describe their demographic characteristics, clinical features and care trajectories, and to assess the mortality rate. Methods: This multicenter cohort study was based on the Electronic Health Records of the Assistance Publique-Hôpitaux de Paris (AP-HP). Cancer patients with a diagnosis of COVID-19 between 3 March and 19 May 2020 were included. Main outcome was all-cause mortality within 30 days of COVID-19 diagnosis. Results: A total of 29,141 cancer patients were identified and 7791 (27%) were tested for SARS-CoV-2. Of these, 1359 (17%) were COVID-19-positive and 1148 (84%) were hospitalized; 217 (19%) were admitted to an intensive care unit. The mortality rate was 33% (383 deaths). In multivariate analysis, mortality-related factors were male sex (aHR = 1.39 [95% CI: 1.07–1.81]), advanced age (78–86 y: aHR = 2.83 [95% CI: 1.78–4.51] vs. <66 y; 86–103 y: aHR = 2.61 [95% CI: 1.56–4.35] vs. <66 y), more than two comorbidities (aHR = 2.32 [95% CI: 1.41–3.83]) and C-reactive protein >20 ng/mL (aHR = 2.20 [95% CI: 1.70–2.86]). Primary brains tumors (aHR = 2.19 [95% CI: 1.08–4.44]) and lung cancer (aHR = 1.66 [95% CI: 1.02–2.70]) were associated with higher mortality. Risk of dying was lower among patients with metabolic comorbidities (aHR = 0.65 [95% CI: 0.50–0.84]). Conclusions: In a hospital-based setting, cancer patients with COVID-19 had a high mortality rate. This mortality was mainly driven by age, sex, number of comorbidities and presence of inflammation. This is the first cohort of cancer patients in which metabolic comorbidities were associated with a better outcome. |
| first_indexed | 2024-03-10T07:05:59Z |
| format | Article |
| id | doaj.art-ab4196a3b85543f9844b5f52bf670088 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T07:05:59Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-ab4196a3b85543f9844b5f52bf6700882023-11-22T15:51:48ZengMDPI AGCancers2072-66942021-09-011319474910.3390/cancers13194749Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort StudyMarc-Antoine Benderra0Ainhoa Aparicio1Judith Leblanc2Demian Wassermann3Emmanuelle Kempf4Gilles Galula5Mélodie Bernaux6Anthony Canellas7Thomas Moreau8Ali Bellamine9Jean-Philippe Spano10Christel Daniel11Julien Champ12Florence Canouï-Poitrine13Joseph Gligorov14on Behalf of the AP-HP/Universities/INSERM COVID-19 Research CollaborationCancer AP-HP Group COVID-19 Task ForceAP-HP Covid CDW Initiative (ACCI)Medical Oncology Department, AP-HP Greater Paris University Hospital, Tenon Hospital, 75020 Paris, FranceClinical Research Platform of East of Paris, AP-HP greater Paris University Hospital, Sorbonne Université Hospitals, 75020 Paris, FranceClinical Research Platform of East of Paris, AP-HP greater Paris University Hospital, Sorbonne Université Hospitals, 75020 Paris, FranceInstitut National de Recherche en Informatique et en Automatique, INRIA Saclay Île-de-France, 78150 Palaiseau, FranceMedical Oncology Department, AP-HP Greater Paris University Hospital, Henri-Mondor Hospital, 94000 Creteil, FranceMedical Oncology Department, AP-HP Greater Paris University Hospital, Tenon Hospital, 75020 Paris, FranceAP-HP Greater Paris University Hospital, DST, 75012 Paris, FranceInstitut Universitaire de Cancérologie AP-HP Sorbonne Université, Sorbonne Université, 75006 Paris, FranceUniversité Paris-Saclay, Inria, CEA, 91120 Palaiseau, FranceAP-HP Greater Paris University Hospital, DSI-WIND, 75006 Paris, FranceInstitut Universitaire de Cancérologie AP-HP Sorbonne Université, Sorbonne Université, 75006 Paris, FranceAP-HP Greater Paris University Hospital, DSI-WIND, 75006 Paris, FranceInstitut National de Recherche en Informatique et en Automatique, INRIA Sophia-Antipolis—ZENITH Team, LIRMM, Montpellier 75646, FrancePublic Health Department, APHP Greater Paris University Hospital, Henri-Mondor Hospital, 94000 Creteil, FranceMedical Oncology Department, AP-HP Greater Paris University Hospital, Tenon Hospital, 75020 Paris, FranceBackground: COVID-19 may be more frequent and more severe in cancer patients than in other individuals. Our aims were to assess the rate of COVID-19 in hospitalized cancer patients, to describe their demographic characteristics, clinical features and care trajectories, and to assess the mortality rate. Methods: This multicenter cohort study was based on the Electronic Health Records of the Assistance Publique-Hôpitaux de Paris (AP-HP). Cancer patients with a diagnosis of COVID-19 between 3 March and 19 May 2020 were included. Main outcome was all-cause mortality within 30 days of COVID-19 diagnosis. Results: A total of 29,141 cancer patients were identified and 7791 (27%) were tested for SARS-CoV-2. Of these, 1359 (17%) were COVID-19-positive and 1148 (84%) were hospitalized; 217 (19%) were admitted to an intensive care unit. The mortality rate was 33% (383 deaths). In multivariate analysis, mortality-related factors were male sex (aHR = 1.39 [95% CI: 1.07–1.81]), advanced age (78–86 y: aHR = 2.83 [95% CI: 1.78–4.51] vs. <66 y; 86–103 y: aHR = 2.61 [95% CI: 1.56–4.35] vs. <66 y), more than two comorbidities (aHR = 2.32 [95% CI: 1.41–3.83]) and C-reactive protein >20 ng/mL (aHR = 2.20 [95% CI: 1.70–2.86]). Primary brains tumors (aHR = 2.19 [95% CI: 1.08–4.44]) and lung cancer (aHR = 1.66 [95% CI: 1.02–2.70]) were associated with higher mortality. Risk of dying was lower among patients with metabolic comorbidities (aHR = 0.65 [95% CI: 0.50–0.84]). Conclusions: In a hospital-based setting, cancer patients with COVID-19 had a high mortality rate. This mortality was mainly driven by age, sex, number of comorbidities and presence of inflammation. This is the first cohort of cancer patients in which metabolic comorbidities were associated with a better outcome.https://www.mdpi.com/2072-6694/13/19/4749SARS-CoV-2 infectionhospitalscancermortality ratemulticenter study |
| spellingShingle | Marc-Antoine Benderra Ainhoa Aparicio Judith Leblanc Demian Wassermann Emmanuelle Kempf Gilles Galula Mélodie Bernaux Anthony Canellas Thomas Moreau Ali Bellamine Jean-Philippe Spano Christel Daniel Julien Champ Florence Canouï-Poitrine Joseph Gligorov on Behalf of the AP-HP/Universities/INSERM COVID-19 Research Collaboration Cancer AP-HP Group COVID-19 Task Force AP-HP Covid CDW Initiative (ACCI) Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study Cancers SARS-CoV-2 infection hospitals cancer mortality rate multicenter study |
| title | Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study |
| title_full | Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study |
| title_fullStr | Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study |
| title_full_unstemmed | Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study |
| title_short | Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study |
| title_sort | clinical characteristics care trajectories and mortality rate of sars cov 2 infected cancer patients a multicenter cohort study |
| topic | SARS-CoV-2 infection hospitals cancer mortality rate multicenter study |
| url | https://www.mdpi.com/2072-6694/13/19/4749 |
| work_keys_str_mv | AT marcantoinebenderra clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT ainhoaaparicio clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT judithleblanc clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT demianwassermann clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT emmanuellekempf clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT gillesgalula clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT melodiebernaux clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT anthonycanellas clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT thomasmoreau clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT alibellamine clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT jeanphilippespano clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT christeldaniel clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT julienchamp clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT florencecanouipoitrine clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT josephgligorov clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT onbehalfoftheaphpuniversitiesinsermcovid19researchcollaboration clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT canceraphpgroupcovid19taskforce clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy AT aphpcovidcdwinitiativeacci clinicalcharacteristicscaretrajectoriesandmortalityrateofsarscov2infectedcancerpatientsamulticentercohortstudy |